NCLH vs RXRX · P/E 16, rev $4.97B vs rev $14.1M
Norwegian Cruise Line Holdings Ltd (NCLH) versus Recursion Pharmaceuticals Inc (RXRX) — a side-by-side from cached financials, not a winner call.
Norwegian Cruise Line Holdings Ltd (NCLH) is a travel services company listed on NYSE.
Recursion Pharmaceuticals Inc (RXRX) is a biotechnology company listed on NASDAQ.
Latest reported NCLH revenue for 2026-06-30 was $4.97B. Net income was $327.2M. NCLH currently screens at market cap $9.10B and trailing P/E 16.0.
Latest reported RXRX revenue for 2026-06-30 was $14.1M. Net income was -$248.5M. RXRX currently screens at market cap $1.75B.
NCLH currently screens at market cap $9.10B and trailing P/E 16.0. RXRX currently screens at market cap $1.75B.
Not investment advice. Open the NCLH and RXRX stock pages for the full models.
Not investment advice.